We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is de... Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate, being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital. Show more
U.S. index futures are virtually flat in pre-market trading this Wednesday, with Wall Street awaiting April’s consumer price index data. At 7:18 AM, Dow Jones futures (DOWI:DJI) were up 3...
CAMBRIDGE, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc.Β (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing...
CAMBRIDGE, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc.Β (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel...
CAMBRIDGE, Mass., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc.Β (Nasdaq: SPRO) (Spero), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.0699 | -4.75510204082 | 1.47 | 1.49 | 1.4 | 86704 | 1.4262283 | CS |
4 | -0.2699 | -16.1616766467 | 1.67 | 1.72 | 1.4 | 135134 | 1.56020461 | CS |
12 | -0.2799 | -16.6607142857 | 1.68 | 1.89 | 1.37 | 302710 | 1.66557403 | CS |
26 | 0.2401 | 20.6982758621 | 1.16 | 1.89 | 1.16 | 249237 | 1.58556582 | CS |
52 | -0.3799 | -21.3426966292 | 1.78 | 1.89 | 0.99 | 257665 | 1.48429556 | CS |
156 | -13.2999 | -90.4755102041 | 14.7 | 19.87 | 0.6801 | 963354 | 2.30642931 | CS |
260 | -9.8799 | -87.5877659574 | 11.28 | 23.639 | 0.6801 | 643601 | 3.53414086 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions